{
    "clinical_study": {
        "@rank": "8271", 
        "acronym": "LUCID", 
        "arm_group": [
            {
                "arm_group_label": "Clonidine", 
                "arm_group_type": "Experimental", 
                "description": "Clonidine administered orally:\nDay 1/loading doses: 75\u00b5g every 3rd hour until maximum 4 doses. Day 2-7/maintenance doses: 75\u00b5g BID. Duration of treatment is maximum 7 days."
            }, 
            {
                "arm_group_label": "Placebo (sugar pill)", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Delirium (\"acute confusional state\")is characterized by an acute decline in attention and\n      cognition, and is a common clinical syndrome in elderly patients.\n\n      The purpose of this randomised, controlled, parallel group pilot trial is to explore\n      superiority of clonidine vs placebo in decreasing delirium in patients diagnosed delirium at\n      the acute geriatric ward.\n\n      We will also study the feasibility of oral clonidine in a geriatric ward and effects of\n      clonidine upon a variety of outcomes as a means to design a more definite study later."
        }, 
        "brief_title": "The Oslo Study of Clonidine in Elderly Patients With Delirium", 
        "condition": "Delirium", 
        "condition_browse": {
            "mesh_term": "Delirium"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient > 65 years old admitted to the acute, medical, geriatric ward\n\n          -  Delirium or subsyndromal delirium diagnosed within the last 48 hours\n\n          -  Signed informed consent from patient or relatives\n\n          -  Expected cooperation of the patients for the treatment and follow up\n\n        Exclusion Criteria:\n\n          -  Symptomatic bradycardia, bradycardia due to sick-sinus-syndrome, second- or third-\n             degree AV-block (not treated With pacemaker) or any other reason causing HR <50 bpm\n             at time of inclusion\n\n          -  Symptomatic hypotension or orthostatic hypotension, or a systolic BP <120 at the time\n             of inclusion\n\n          -  Ischemic stroke within the last 3 months or critical peripheral ischemia\n\n          -  Acute coronary syndrome, unstable or severe coronary heart disease (symptoms at\n             minimal physical activity; NYHA 3 and 4) and moderate to severe heart failure (NYHA 3\n             and 4).\n\n          -  A diagnosis of polyneuropathy or pheochromocytoma\n\n          -  Renal insufficiency (estimated GFR<30 ml/min according to the MDRD formula).\n\n          -  Body weight < 45 kg.\n\n          -  Considered as moribund on admission.\n\n          -  Not able to take oral medications\n\n          -  Current use of tricyclic antidepressants, monoamine reuptake inhibitors or\n             ciclosporin\n\n          -  Previously included in this study\n\n          -  Adverse reactions to clonidine or excipients (lactose, saccharose)\n\n          -  Not speaking or reading Norwegian\n\n          -  Any other condition as evaluated by the treating physician"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01956604", 
            "org_study_id": "2013-000815-26", 
            "secondary_id": "2013-000815-26"
        }, 
        "intervention": [
            {
                "arm_group_label": "Clonidine", 
                "intervention_name": "Clonidine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo (sugar pill)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Clonidine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 14, 2014", 
        "location": {
            "contact": {
                "email": "t.b.wyller@medisin.uio.no", 
                "last_name": "Bruun Wyller"
            }, 
            "facility": {
                "address": {
                    "city": "Oslo", 
                    "country": "Norway", 
                    "zip": "N-0424"
                }, 
                "name": "Oslo University Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Bj\u00f8rn Erik Neerland, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Karen Roksund Hov, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Norway"
        }, 
        "number_of_arms": "2", 
        "other_outcome": {
            "description": "We will also do per protocol analyses and exposure-response analyses based on measurements of the plasma concentration of clonidine", 
            "measure": "Exposure-response analyses", 
            "safety_issue": "No", 
            "time_frame": "4 months"
        }, 
        "overall_contact": {
            "email": "t.b.wyller@medisin.uio.no", 
            "last_name": "Torgeir Bruun Wyller, MD PhD", 
            "phone": "+47 91166682"
        }, 
        "overall_official": {
            "affiliation": "Oslo University Hospital", 
            "last_name": "Torgeir Bruun Wyller, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Norway:National Committee for Medical and Health Research Ethics", 
                "Norway: Norwegian Medicines Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "MDAS (Memorial delirium assessment scale)", 
            "safety_issue": "No", 
            "time_frame": "Participants will be followed for the duration of hospital stay, an expected average of approximately 2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01956604"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "We will compare the actively treated group with the placebo group (also with subanalyses for subsyndromal delirium and hypoactive/ hyperactive/ mixed delirium) with respect to:\n\u2022  time to first resolution, monitored by DSM-5 criteria", 
                "measure": "Time-to-first delirium", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "description": "\u2022 monitored by DSM-5 criteria", 
                "measure": "Incidence of \"full-scale\" delirium", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "description": "measured by MDAS, OSLA", 
                "measure": "Severity of delirium", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "description": "Measured by MDAS, OSLA", 
                "measure": "Delirium subtype", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "measure": "The use of \"rescue medication\"", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "measure": "Length of hospital stay", 
                "safety_issue": "No", 
                "time_frame": "Hospital stay"
            }, 
            {
                "measure": "Patient distress", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "measure": "Side effects of clonidine", 
                "safety_issue": "Yes", 
                "time_frame": "4 months"
            }, 
            {
                "measure": "Pharmacokinetic response to clonidine", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Pharmacodynamic response to clonidine", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "measure": "Biomarkers", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "measure": "Institutionalization", 
                "safety_issue": "No", 
                "time_frame": "4 months"
            }, 
            {
                "measure": "Survival", 
                "safety_issue": "No", 
                "time_frame": "4 months"
            }, 
            {
                "measure": "Cognitive function/ independence", 
                "safety_issue": "No", 
                "time_frame": "4 months"
            }
        ], 
        "source": "Oslo University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Oslo University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}